Deloitte Radical Interoperability Survey Results
Deloitte-audit, consulting, tax, and advisory services company-announced the results of its Radical Interoperability survey, conducted by the Deloitte Center for Health Solutions.
The report provides insights for healthcare stakeholders that want to emerge as a leader in their use of data and analytics in the future of health. This includes the need to prioritize interoperability at the leadership level; developing a bold investment strategy that focuses on strategic, future-looking opportunities; and leveraging the coming compliance, privacy, and security regulations as a key catalyst to drive enterprise momentum.
The report identifies that while regulations are one of the biggest drivers (47%) for broader interoperability, value-based care is the greatest driver (51%) in this pursuit. Furthermore, a recognition of consumer demand for transparency and access-particularly among younger generations-is one of the top drivers (41%).
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
